About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Multiple Sclerosis Patients may Benefit from the Drug Alemtuzumab
Advertisement

Alemtuzumab Drug may Reverse Disability in Patients with Multiple Sclerosis

Font : A-A+

Highlights
  • Alemtuzumab is a drug prescribed for multiple sclerosis patients who do not respond to other drugs.
  • Multiple sclerosis drugs could reverse physical disability caused by the disease, claims a new study.
  • Patients who received alemtuzumab had improved on a disability test by at least one point.
  • The drug also improved the thinking skills of the patients with multiple sclerosis.


Multiple sclerosis is a disabling disease that affects the brain and spinal cord. A drug called alemtuzumab could reverse some of the physical disability caused by multiple sclerosis, claims a new research.

Alemtuzumab could cause some serious side effects. Thus, it is not prescribed for all the patients with multiple sclerosis. However, it is prescribed for people who have not responded well to other multiple sclerosis drugs. Alemtuzumab is used in relapsing-remitting multiple sclerosis, which is the most common form of the disease. In relapsing-remitting multiple sclerosis, the symptoms alternate between sudden worsening and remission.

Advertisement


Relapsing-remitting multiple sclerosis is characterized by increased disease activity and worsening symptoms. The disease does not progress, but the symptoms may improve or disappear during remission. In the current study, alemtuzumab was used early in the course of multiple sclerosis treatments.

Dr. Gavin Giovannon, of Queen Mary University of London, United Kingdom, also lead author of the study, said, "While many multiple sclerosis drugs slow the progress of disability, there have been little data about the ability of current treatments to help restore function previously lost to MS."
Advertisement

Alemtuzumab Could Reverse Physical Disability in Multiple Sclerosis Patients

The researchers recruited people with relapsing-remitting multiple sclerosis who did not respond well to other drugs. The participants were divided into two groups. Group one comprised of 426 people who were treated with alemtuzumab. Group two comprised a total of 202 participants who were treated with the drug interferon beta-1a.

Disability Test

The participants' level of disability were assessed at the beginning of the study and again every three months for two years. At the end of the study period, the results showed that nearly 28 percent of the participants who received alemtuzumab had improved by at least one point in the disability test, with the scores ranging from 0 to 10. While the participants' who received the drug interferon beta-1a showed improvement by only 15 percent.

The researchers adjusted the results to ensure that the improvements were not driven by people recovering from recent relapses. The findings also showed that people who received alemtuzumab were 2.5 times more likely to improve the assessment of thinking skills when compared to those who received interferon. The alemtuzumab group was also more than twice as likely to improve the ability to move without tremor or clumsy movements known as ataxia.

Lead researcher Giovannoni said that if the benefits of alemtuzumab were confirmed, the risks associated with the drug should also be considered. The risks include serious and rarely fatal autoimmune problems as well as infusion reactions.

Dr. Bibiana Bielekova, of the National Institute of Neurological Disorders and Stroke in Bethesda, said, "These results are encouraging, but exactly how alemtuzumab may reverse the damage, whether it's through repairing myelin, creating new nerve synapses, greatly reducing inflammation or some other mechanism, is yet to be investigated."

"Longer studies are also needed to see how many people experience, or do not experience, improvement in disability over longer periods of time," added Dr. Bielekova, who is a Fellow of the American Academy of Neurology.

The study is published in the journal Neurology, a medical journal of the American Academy of Neurology.

Multiple Sclerosis

The immune system attacks the myelin (protective sheath that covers nerve fibers). The symptoms include blurred vision, loss of balance, poor coordination, tremors, fatigue, problems with memory and concentration. The symptoms may worsen over time. The damage can cause communication problems between the brain and the body. Multiple sclerosis can cause the nerves to deteriorate and become permanently damaged.

Facts About Multiple Sclerosis

  • Multiple sclerosis affects more than 2,500,000 people in the world.
  • More than 400,000 people in the United States have multiple sclerosis.
  • More than one million new cases are diagnosed in India.
  • Multiple sclerosis affects more women than men. It begins between the ages of 20 and 40.
  • People with type 1 diabetes, thyroid disorder, and inflammatory bowel disease are at increased risk of developing multiple sclerosis.
References :
  1. MS drug may reverse some physical disability - https://www.eurekalert.org/emb_releases/2016-10/aaon-mdm100716.php)
  2. Multiple Sclerosis - (https://medlineplus.gov/multiplesclerosis.html)
  3. Overview Multiple sclerosis - (http://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/home/ovc-20131882)
  4. What is multiple sclerosis? - (http://www.nationalmssociety.org/What-is-MS/MS-FAQ-s)
Source: Medindia

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Shirley Johanna. (2016, October 13). Alemtuzumab Drug may Reverse Disability in Patients with Multiple Sclerosis. Medindia. Retrieved on May 16, 2022 from https://www.medindia.net/news/healthinfocus/multiple-sclerosis-patients-may-benefit-from-the-drug-alemtuzumab-164243-1.htm.

  • MLA

    Shirley Johanna. "Alemtuzumab Drug may Reverse Disability in Patients with Multiple Sclerosis". Medindia. May 16, 2022. <https://www.medindia.net/news/healthinfocus/multiple-sclerosis-patients-may-benefit-from-the-drug-alemtuzumab-164243-1.htm>.

  • Chicago

    Shirley Johanna. "Alemtuzumab Drug may Reverse Disability in Patients with Multiple Sclerosis". Medindia. https://www.medindia.net/news/healthinfocus/multiple-sclerosis-patients-may-benefit-from-the-drug-alemtuzumab-164243-1.htm. (accessed May 16, 2022).

  • Harvard

    Shirley Johanna. 2021. Alemtuzumab Drug may Reverse Disability in Patients with Multiple Sclerosis. Medindia, viewed May 16, 2022, https://www.medindia.net/news/healthinfocus/multiple-sclerosis-patients-may-benefit-from-the-drug-alemtuzumab-164243-1.htm.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
Drinking This Popular Beverage May Drop Dementia Risk
Worst Mistakes Parents Make When Talking to Kids
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Drugs Banned in India Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

Most Popular on Medindia

Nutam (400mg) (Piracetam) Color Blindness Calculator Accident and Trauma Care Blood Pressure Calculator Hearing Loss Calculator Indian Medical Journals Blood Donation - Recipients Blood - Sugar Chart Turmeric Powder - Health Benefits, Uses & Side Effects Vent Forte (Theophylline)

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use